daaimon

daaimon is an independent research company focusing on healthcare and consumer sectors across developed and emerging markets. We produce insightful research which challenges conventional thinking. In particular, we look for new ideas by testing consensus forecasts and markets expectations.

Innovent Biologics (1801 HK) – Time to Take Profits (Bearish)

Novo Nordisk: Is the FDA Approval of Wegovy Worth an Extra $460 Bn?

The United Laboratories Company Ltd (3933 HK) - A Sub Five PE Bargain!

Innovent Biologics(1801 HK)– More than Just a GLP-1 Play

Healthcare Equity Analyst - Emerging & Dev Markets, daaimon

Avien Pillay

Healthcare Equity Analyst - Emerging & Dev Markets

Independent Insight Provider

Equity Bottom-Up

<ul>
<li>Novo Nordisk A/S drops 23% after the latest profit warnings</li>
<li>All GLP-1gains have now been erased and it is back to 2022 price levels</li>
<li>It is currently cheap, but we are not sure this is the end of the bad news</li>
</ul>


Novo Nordisk A/S drops 23% after the latest profit warnings
All GLP-1gains have now been erased and it is back to 2022 price levels
It is currently cheap, but we are not sure this is the end of the bad news


All GLP-1 Gains Have Now Been Erased from Novo Nordisk A/S (NVO US)